Exploiting antitumor immunity to overcome relapse and improve remission duration

Area of Science:

• Oncology
• Immunology
• Cancer Therapy

Background:

• Cancer relapse is often driven by drug-resistant clones and tumor stem cells.
• Preclinical studies show patient lymphocytes can be activated to kill tumor cells.
• Gastrointestinal stromal tumor (GIST) presents challenges in treatment due to resistance and recurrence.

Purpose of the Study:

• To evaluate the safety and efficacy of combining peginterferon α-2b with imatinib for advanced GIST.
• To assess the combination's ability to induce antitumor immunity, specifically a Th1 response and NK cell activation.
• To determine clinical outcomes including response rates, overall survival, and progression-free survival.

Main Methods:

• A clinical trial combining peginterferon α-2b and imatinib was designed for stage III/IV GIST patients.
• Peginterferon α-2b was used to promote antitumor immunity, while imatinib targeted tumor cells and reduced tolerance.
• Interim analysis assessed immune responses (IFN-γ-producing cells) and clinical outcomes (CR, PR, OS, PFS).

Main Results:

• Interim analysis in eight patients showed significant induction of IFN-γ-producing CD8+, CD4+, NK cells, and tumor-infiltrating lymphocytes.
• A strong Th1 response and NK cell activation were observed.
• After a median follow-up of 3.6 years, 100% overall response (CR+PR) and 100% overall survival were achieved.
• Six of seven evaluable patients had PFS exceeding established benchmarks for imatinib monotherapy.

Conclusions:

• The combination of targeted therapy (imatinib) and immunotherapy (peginterferon α-2b) is safe for GIST treatment.
• This combination therapy induces significant Th1 response and NK cell activation.
• The approach demonstrated highly promising clinical efficacy in GIST, suggesting potential for other cancer types.